Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, Harry G M ; McKone, Edward F ; Downey, Damian G ; Van Braeckel, Eva ; Rowe, Steven M ; Tullis, Elizabeth ; Mall, Marcus A ; Welter, John J ; Ramsey, Bonnie W ; McKee, Charlotte M ; Marigowda, Gautham ; Moskowitz, Samuel M ; Waltz, David ; Sosnay, Patrick R ; Simard, Christopher ; Ahluwalia, Neil ; Xuan, Fengjuan ; Zhang, Yaohua ; Taylor-Cousar, Jennifer L ; McCoy, Karen S ; McCoy, Karen ; Donaldson, Scott ; Walker, Seth ; Chmiel, James ; Rubenstein, Ronald ; Froh, Deborah K. ; Neuringer, Isabel ; Jain, Manu ; Moffett, Kathryn ; Taylor-Cousar, Jennifer L. ; Barnett, Bruce ; Mueller, Gary ; Flume, Patrick ; Livingston, Floyd ; Mehdi, Nighat ; Teneback, Charlotte ; Welter, John ; Jain, Raksha ; Kissner, Dana ; Patel, Kapilkumar ; Calimano, Francisco J. ; Johannes, Jimmy ; Daines, Cori ; Keens, Thomas ; Scher, Herschel ; Chittivelu, Subramanyam ; Reddivalam, Sudhakar ; Klingsberg, Ross Carl ; Johnson, Larry G. ; Verhulst, Stijn ; Macedo, Patricia ; Downey, Damien ; Connett, Gary ; Nash, Edward ; Withers, Nicholas ; Lee, Timothy ; Bakker, Marleen ; Heijerman, Harry ; Vermeulen, Francois ; Van Braeckel, Eva ; Knoop, Christiane ; De Wachter, Elke ; van der Meer, Renske ; Merkus, Petrus ; Majoor, Christof

The Lancet (British edition), 2019-11, Vol.394 (10212), p.1940-1948 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível